The world of life sciences is more dynamic than ever—new drugs, new therapies, new medical devices, and improvements and groundbreaking solutions are coming faster and faster. The COVID-19 crisis will add additional risk factors for Life Sciences companies around disclosures and financing. The downside is that not everything pans out, or perhaps takes longer than anticipated or meets unexpected competition from another innovative company. So in the world of D&O, disclosures are integral to the success of a life sciences company in terms of either preventing D&O or minimizing the costs of a securities class-action (SCA) lawsuit.